Reports Q1 revenue $11.49B, consensus $10.92B. “We are off to a good start in 2026, with first quarter results reflecting sustained momentum across our Growth Portfolio and disciplined execution throughout the business,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers (BMY) Squibb. “With multiple pivotal data readouts and opportunities ahead, we remain focused on advancing our differentiated pipeline and translating this progress into meaningful outcomes for patients and shareholders.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers Squibb Posts Q1 2026 Results, Reaffirms Outlook
- Options Volatility and Implied Earnings Moves Today, April 30, 2026
- Notable companies reporting before tomorrow’s open
- BMY Upcoming Earnings Report: What to Expect?
- Options Volatility and Implied Earnings Moves This Week, April 27 – May 01, 2026